HIT vs EVLV vs HIMS vs OSIS

For growth investors, Health In Tech, Inc.

(HIT) is the stronger pick with 71. 0% revenue growth year-over-year, versus 11. 3% for OSI Systems, Inc. (OSIS). OSI Systems, Inc. (OSIS) offers the better valuation at 27. 7x trailing P/E (23. 0x forward), making it the more compelling value choice. Analysts rate Evolv Technologies Holdings, Inc. (EVLV) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, OSI Systems, Inc.

(OSIS) is the cheapest at 27. 7x versus Health In Tech, Inc. at 78. 5x. On forward P/E, OSI Systems, Inc. is actually cheaper at 23. 0x.

Over the past 5 years, OSI Systems, Inc.

(OSIS) delivered a total return of +149. 9%, compared to -69. 2% for Health In Tech, Inc. (HIT). Over 10 years, the gap is even starker: OSIS returned +372. 9% versus HIT's -69. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Evolv Technologies Holdings, Inc.

(EVLV) is the lower-risk stock at 1. 23β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 95% more volatile than EVLV relative to the S&P 500. On balance sheet safety, Health In Tech, Inc. (HIT) carries a lower debt/equity ratio of 1% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Health In Tech, Inc.

(HIT) is pulling ahead at 71. 0% versus 11. 3% for OSI Systems, Inc. (OSIS). On earnings-per-share growth, the picture is similar: Health In Tech, Inc. grew EPS 62. 6% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIT leads at 79. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

OSI Systems, Inc.

(OSIS) is the more profitable company, earning 8. 7% net margin versus -22. 7% for Evolv Technologies Holdings, Inc. — meaning it keeps 8. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OSIS leads at 12. 7% versus -30. 7% for EVLV. At the gross margin level — before operating expenses — HIT leads at 62. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, OSI Systems, Inc.

(OSIS) trades at 23. 0x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 28. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EVLV: 40. 2% to $10. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, OSI Systems, Inc.

(OSIS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+372. 9% 10Y return). Health In Tech, Inc. (HIT) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OSIS: +372. 9%, HIT: -69. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HIT (Technology) and EVLV (Industrials) and HIMS (Healthcare) and OSIS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HIT is a small-cap high-growth stock; EVLV is a small-cap high-growth stock; HIMS is a small-cap high-growth stock; OSIS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.